Highlights Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 02:30:02 07/03/2026 am IST			5-day change	1st Jan Change
990.33 ^USD	+0.72%		-5.86%	-7.85%

07/03	Eli Lilly says CEO David A. Ricks' 2025 total compensation was $36.7 million - SEC filing	RE
06/03	Who Foundation announces collaboration with Lilly to strengthen health systems for obesity care	RE

Highlights

06/03	GoodRx Collaborates With Eli Lilly To Expand Employer-Sponsored Access To Zepbound KwikPen	CI
05/03	Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options	CI
05/03	Global markets live: Broadcom, Berkshire Hathaway, Morgan Stanley, Intel, Eli Lilly…
05/03	GLP-1 drugs protect against new or worsening addictions, large study shows	RE
05/03	Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others.	CI
04/03	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis	CI
04/03	When Talk of Talks Moves Markets
03/03	Aspen Pharmacare expects Canada entry with Ozempic generic by third quarter	RE
03/03	Short war? Long war?
03/03	Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval (March 2)	RE
03/03	US asks smaller drugmakers to discuss lowering prices for Medicaid	RE
02/03	Lantheus Holdings, Inc. Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate, Radioequivalent to Lutathera	CI
28/02	Sector Update: Health Care Stocks Advance Late Afternoon	MT
27/02	Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata	CI
27/02	Eli Lilly, Incyte Say They Get EMA Panel's Positive Opinion for Olumiant to Treat Severe Alopecia Areata	MT
26/02	Eli Lilly and Company Announces Detailed Results from ACHIEVE-3	CI
25/02	RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030	MT
25/02	Pfizer Gets Full FDA Approval for Braftovi Combination for Colon Cancer Treatment	MT
24/02	A Record High for the CAC 40, Other European Indices More Cautious
24/02	Eli Lilly's Breast Cancer Drug Inluriyo Approved by UK Regulator	MT
24/02	UK Medicines Regulator OKs Eli Lilly's New Treatment for Breast Cancer	MT
24/02	UK's MHRA approves Imlunestrant Tosylate (Inluriyo) for treatment of breast cancer	RE
24/02	Barclays slashes sales forecasts for Novo's CagriSema by more than 80%	RE
24/02	Pfizer Acquires Exclusive Rights to Obesity Drug in China	DJ
24/02	US stocks end sharply lower amid AI fears, tariff angst	RE